Understanding how immune cells recognize sugars to improve vaccines
Molecular Mechanisms for Carbohydrate Presentation to CD4+ T cells by MHCII Pathway
This work explores how our immune system's T cells recognize sugar molecules from bacteria, aiming to create more effective vaccines against infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11145755 on NIH RePORTER |
What this research studies
Many harmful bacteria have sugar coatings that our immune system can recognize, leading to the production of protective antibodies. Current vaccines that use these sugars are effective but could be much better if we understood more about how our immune cells, specifically T cells, respond to them. Our team has found a special type of T cell, called Tcarbs, that recognizes these sugar molecules. This project builds on that discovery to uncover the exact steps these T cells take to recognize bacterial sugars, which could lead to a new way of designing vaccines.
Who could benefit from this research
Good fit: This foundational research is not recruiting patients directly but aims to benefit anyone susceptible to bacterial infections that are currently targeted by glycoconjugate vaccines.
Not a fit: Patients who are not susceptible to bacterial infections or whose conditions are unrelated to the immune system's response to carbohydrates may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new, more powerful vaccines that better protect people from serious bacterial infections.
How similar studies have performed: Our team has made previous discoveries and gathered preliminary data supporting the existence of T cells that recognize carbohydrates, suggesting a promising foundation for this new approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Avci, Fikri Y — Emory University
- Study coordinator: Avci, Fikri Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.